Big pharma moves from 'blockbusters' to 'niche busters'
Big pharma moves from 'blockbusters' to 'niche busters'
About this item
Full title
Author / Creator
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Since its passage in 1983, the US Orphan Drug Act has led to the approval of more than 350 drugs for around 200 rare diseases, mostly thanks to small biotech startups looking for a unique niche in the marketplace. Yet with the demise of big pharma's traditional business model, some of the worlds largest drug makers are aggressively entering the rar...
Alternative Titles
Full title
Big pharma moves from 'blockbusters' to 'niche busters'
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_748955787
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_748955787
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/nm0810-837a
